SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]:
SEC Accession No. 0001558370-17-004382
Filing Date
2017-05-16
Accepted
2017-05-16 16:05:16
Documents
53
Period of Report
2017-03-31

Document Format Files

Seq Description Document Type Size
1 6-K sbbp-20170331x6k.htm 6-K 1098656
2 EX-10.1 sbbp-20170331ex101553f49.htm EX-10.1 145794
  Complete submission text file 0001558370-17-004382.txt   4419534

Data Files

Seq Description Document Type Size
3 EX-101.INS sbbp-20170331.xml EX-101.INS 831983
4 EX-101.SCH sbbp-20170331.xsd EX-101.SCH 35022
5 EX-101.CAL sbbp-20170331_cal.xml EX-101.CAL 43410
6 EX-101.DEF sbbp-20170331_def.xml EX-101.DEF 111269
7 EX-101.LAB sbbp-20170331_lab.xml EX-101.LAB 349034
8 EX-101.PRE sbbp-20170331_pre.xml EX-101.PRE 248031
Mailing Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053
Business Address 900 NORTHBROOK DRIVE, SUITE 200 TREVOSE PA 19053 (610) 254-9200
Strongbridge Biopharma plc (Filer) CIK: 0001634432 (see all company filings)

IRS No.: 981130690 | State of Incorp.: L2
Type: 6-K | Act: 34 | File No.: 001-37569 | Film No.: 17848624
SIC: 2834 Pharmaceutical Preparations